Back pain in patients with severe osteoporosis on teriparatide or antiresorptives: a prospective observational study in a multiethnic population

Share this Article

Singapore Med J 2014; 55(9): 493-501; http://dx.doi.org/10.11622/smedj.2014120

Songpatanasilp T, Mumtaz M, Chhabra H, Yu M, Sorsaburu S
Correspondence: Dr Thawee Songpatanasilp, thaweesps@yahoo.com

ABSTRACT
INTRODUCTION We evaluated reduced back pain in a multiethnic population treated with teriparatide and/or antiresorptives in real-life clinical settings over 12 months.
METHODS This prospective observational study comprised 562 men and postmenopausal women (mean age 68.8 years) receiving either teriparatide (n = 230), antiresorptives (raloxifene or bisphosphonates; n = 322), or both (n = 10) for severe osteoporosis. The primary endpoint was the relative risk of new/worsening back pain at six months.
RESULTS At baseline, a higher proportion of teriparatide-treated than antiresorptive-treated patients had severe back pain (30.9% vs. 17.7%), extreme pain/discomfort (25.3% vs. 16.8%), extreme anxiety/depression (16.6% vs. 7.8%) and were confined to bed (10.0% vs. 5.3%). Teriparatide-treated patients had higher visual analog scale (VAS) scores for pain (5.8 ± 2.42 vs. 5.1 ± 2.58) and lower mean European Quality of Life-5 Dimensions (EQ-5D) scores (37.7 ± 29.15 vs. 45.5 ± 31.42) than antiresorptive-treated patients. The incidence of new/worsening back pain at six months for patients on teriparatide and antiresorptives was 9.8% and 10.3% (relative risk 0.99, 95% confidence interval 0.80–1.23), respectively. The incidence of severe back pain at 12 months was 1.3% and 1.6% in the teriparatide and antiresorptive treatment groups, respectively. Teriparatide-treated patients had lower mean VAS (2.71 ± 2.21 vs. 3.30 ± 2.37) and EQ?5D (46.1 ± 33.18 vs. 55.4 ± 32.65) scores at 12 months. More teriparatide-treated patients felt better (82.7% vs. 71.0%) and were very satisfied with treatment (49.4% vs. 36.8%) compared to antiresorptive-treated patients.
CONCLUSION Patients treated with either teriparatide or antiresorptives had similar risk of new/worsening back pain at six months.

Keywords: antiresorptives, back pain, EQ-5D, osteoporosis, teriparatide
Singapore Med J 2014; 55(9): 493-501; http://dx.doi.org/10.11622/smedj.2014120

REFERENCES

1. Silverman SL, Piziak VK, Chen P, Misurski DA, Wagman RB. Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis. J Rheumatol 2005; 32:2405-9. PMid:16331772

2. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348:1535-41. http://dx.doi.org/10.1016/S0140-6736(96)07088-2

3. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999; 282:1344-52. http://dx.doi.org/10.1001/jama.282.14.1344

4. Guyatt GH, Cranney A, Griffith L, et al. Summary of meta-analyses of therapies for postmenopausal osteoporosis and the relationship between bone density and fractures. Endocrinol Metab Clin North Am 2002; 31:659?79, xii. http://dx.doi.org/10.1016/S0889-8529(02)00024-5

5. Delmas PD, Recker RR, Chesnut CH 3rd, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporosos Int 2004; 15:792-8. http://dx.doi.org/10.1007/s00198-004-1602-9

6. Russell RG, Rogers MJ, Frith JC, et al. The pharmacology of bisphosphonates and new insights into their mechanisms of action. J Bone Miner Res 1999; 14 suppl 2:53-65. http://dx.doi.org/10.1002/jbmr.5650140212

7. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344:1434-41. http://dx.doi.org/10.1056/NEJM200105103441904

8. Jiang Y, Zhao JJ, Mitlak BH, et al. Recombinant human parathyroid hormone (1-34)[teriparatide]improves both cortical and cancellous bone structure. J Bone Miner Res 2003; 18:1932-41. http://dx.doi.org/10.1359/jbmr.2003.18.11.1932

9. Kaufman JM, Orwoll E, Goemaere S, et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 2005; 16:510-16. http://dx.doi.org/10.1007/s00198-004-1713-3

10. Liberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995; 333:1437-43. http://dx.doi.org/10.1056/NEJM199511303332201

11. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280:2077-82. http://dx.doi.org/10.1001/jama.280.24.2077

12. Chesnut CH 3rd, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000; 109:267-76. http://dx.doi.org/10.1016/S0002-9343(00)00490-3

13. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999; 282:637-45. http://dx.doi.org/10.1001/jama.282.7.637

14. Jakob F, Oertel H, Langdahl B, et al. Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study. Eur J Endocrinol 2012; 166:87-97. http://dx.doi.org/10.1530/EJE-11-0740

15. Fahrleitner-Pammer A, Langdahl BL, Marin F. et al. Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS). Osteoporos Int 2011; 22:2709-19. http://dx.doi.org/10.1007/s00198-010-1498-5

16. Lyritis G, Marin F, Barker C, et al. Back pain during different sequential treatment regimens of teriparatide: results from EUROFORS. Curr Med Res Opin 2010; 26:1799-807. http://dx.doi.org/10.1185/03007995.2010.488516

17. Nevitt MC, Chen P, Dore RK, et al. Reduced risk of back pain following teriparatide treatment: a meta-analysis. Osteoporos Int 2006; 17:273-80. http://dx.doi.org/10.1007/s00198-005-2013-2

18. Nevitt MC, Chen P, Kiel DP, et al. Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysis. Osteoporos Int 2006; 17:1630-7. http://dx.doi.org/10.1007/s00198-006-0177-z

19. Hadji P, Zanchetta JR, Russo L, et al. The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures. Osteoporos Int 2012; 23:2141-50. http://dx.doi.org/10.1007/s00198-011-1856-y

20. Miyauchi A, Matsumoto T, Shigeta H, et al. Effect of teriparatide on bone mineral density and biochemical markers in Japanese women with postmenopausal osteoporosis: a 6-month dose-response study. J Bone Miner Metab 2008; 26:624-34. http://dx.doi.org/10.1007/s00774-008-0871-3

21. Choi WH, Kim GS, Lim SK, et al. Comparison of teriparatide and calcitonin treatment in postmenopausal Korean women with osteoporosis. J Korean Soc Osteoporos 2005; 3:110-120.

22. Dai KR, Chen DC, Zhang ZL, et al. Comparison of the effects of subcutaneous teriparatide and intranasal calcitonin in treating established osteoporosis in postmenopausal Chinese women. Chin J Osteoporos Bone Miner Res 2011; 4:23-31.

23. Hwang JS, Tu ST, Yang TS, et al. Teriparatide vs. calcitonin in the treatment of Asian postmenopausal women with established osteoporosis. Osteoporos Int 2006; 17:373-8. http://dx.doi.org/10.1007/s00198-005-2002-5

24. Kung AW, Pasion EG, Sofiyan M, et al. A comparison of teriparatide and calcitonin therapy in postmenopausal Asian women with osteoporosis: a 6-month study. Curr Med Res Opin 2006; 22:929-37. http://dx.doi.org/10.1185/030079906X104768

25. Miyauchi A, Matsumoto T, Sugimoto T, et al. Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases. Bone 2010; 47:493-502. http://dx.doi.org/10.1016/j.bone.2010.05.022

26. Reginster JY, Collette J, Neuprez A, et al. Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy. Bone 2008; 42:832-6. http://dx.doi.org/10.1016/j.bone.2008.01.021

27. Chinese Society of Osteoporosis and Bone Mineral Diseases branch. Diagnosis and treatment of primary osteoporosis guide (2011). Chin J Osteoporos Bone Miner Res 2011; 4:2-17.

28. Mithal A, Dhingra V, Lau E. The Asian Audit: Epidemiology, costs and burden of osteoporosis in Asia 2009. Switzerland: International Osteoporosis Foundation, 2009. PMCid:PMC2836750

29. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001; 33:337?43. http://dx.doi.org/10.3109/07853890109002087

30. Body JJ, Gaich GA, Scheele WH, et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)]with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002; 87:4528-35. http://dx.doi.org/10.1210/jc.2002-020334

31. Kallmes DF, Comstock BA, Heagerty PJ, et al, A randomized trial of vertebroplasty for osteoporotic spinal fractures. N Engl J Med 2009; 361:569-79. http://dx.doi.org/10.1056/NEJMoa0900563

32. McClung MR, San Martin J, Miller PD, et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 2005; 165:1762-8. http://dx.doi.org/10.1001/archinte.165.15.1762

33. Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007; 357:2028-39. http://dx.doi.org/10.1056/NEJMoa071408

34. Saag KG, Zanchetta JR, Devogelaer JP, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 2009; 60:3346-55. http://dx.doi.org/10.1002/art.24879